Asthma – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult Asthma (US) 2024

Two types of pharmacotherapy are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA). Maintenance therapies are inhaled, oral, or biological drugs that are used to prevent exacerbations by targeting the underlying pathophysiology (e.g., a LABA/ICS such as GlaxoSmithKline’s Advair, an anti-IL-5 agent such as AstraZeneca’s Fasenra). Many adult patients receive several agents to treat their asthma. Although multiple well-established therapies are available, the market has seen the approval and launch of even more agents, including novel biologics (e.g., AstraZeneca’s Tezspire) and generic versions of blockbuster inhaled drugs (e.g., albuterol sulfate, formoterol / budesonide). These launches have added treatment options and fueled more-intense competition in this market.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult asthma patients?
  • How have newer biologics such as Tezspire and Dupixent been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of adult asthma patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of adult asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Content highlights

Markets covered: United States

Key companies: GlaxoSmithKline, AstraZeneca, Teva, Genentech, Merck, Boehringer Ingelheim, Sanofi, Regeneron, Mylan, Cipla, Par, Perrigo, Prasco

Key drugs: Advair, Symbicort, Dulera, AirDuo, Breo, Dupixent, Fasenra, Nucala, Ventolin, ProAir, montelukast sodium, Flovent, Qvar, Spiriva, Tezspire, Trelegy

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key Feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

launch Related Market Assessment Reports